142 related articles for article (PubMed ID: 20101852)
21. Limited utility of tartrate-resistant acid phosphatase isoform 5b in assessing response to therapy in osteoporosis.
Brady JJ; Crowley RK; Murray BF; Kilbane MT; O'Keane M; McKenna MJ
Ir J Med Sci; 2014 Mar; 183(1):47-52. PubMed ID: 23737138
[TBL] [Abstract][Full Text] [Related]
22. Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption.
Halleen JM; Tiitinen SL; Ylipahkala H; Fagerlund KM; Väänänen HK
Clin Lab; 2006; 52(9-10):499-509. PubMed ID: 17078477
[TBL] [Abstract][Full Text] [Related]
23. Tartrate-resistant acid phosphatase 5b as serum marker of bone metabolism in cancer patients.
Mose S; Menzel C; Kurth AA; Obert K; Breidert I; Borowsky K; Böttcher HD
Anticancer Res; 2003; 23(3C):2783-8. PubMed ID: 12926113
[TBL] [Abstract][Full Text] [Related]
24. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E
Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645
[TBL] [Abstract][Full Text] [Related]
25. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption.
Hannon RA; Clowes JA; Eagleton AC; Al Hadari A; Eastell R; Blumsohn A
Bone; 2004 Jan; 34(1):187-94. PubMed ID: 14751577
[TBL] [Abstract][Full Text] [Related]
26. Suitability of tartrate-resistant acid phosphatase type 5b as a screening marker for bone mineral density in community-dwelling elderly individuals.
Irie S; Hayashida N; Shinkawa T; Taira Y; Sekitani Y; Teraoka S; Hashiguchi K; Yoshida K; Morishita M; Takamura N
Tohoku J Exp Med; 2011 Jun; 224(2):105-10. PubMed ID: 21597244
[TBL] [Abstract][Full Text] [Related]
27. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY
Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059
[TBL] [Abstract][Full Text] [Related]
28. Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer.
Wada N; Ishii S; Ikeda T; Enomoto K; Kitajima M
Anticancer Res; 1999; 19(5C):4515-21. PubMed ID: 10650803
[TBL] [Abstract][Full Text] [Related]
29. Tartrate-resistant acid phosphate activity as osteoclastic marker: sensitivity of cytochemical assessment and serum assay in comparison with standardized osteoclast histomorphometry.
Ballanti P; Minisola S; Pacitti MT; Scarnecchia L; Rosso R; Mazzuoli GF; Bonucci E
Osteoporos Int; 1997; 7(1):39-43. PubMed ID: 9102061
[TBL] [Abstract][Full Text] [Related]
30. Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium.
Alatalo SL; Halleen JM; Hentunen TA; Mönkkönen J; Väänänen HK
Clin Chem; 2000 Nov; 46(11):1751-4. PubMed ID: 11067809
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of immunoassays for type-5 tartrate-resistant acid phosphatase.
Nakasato YR; Janckila AJ; Halleen JM; Vaananen HK; Walton SP; Yam LT
Clin Chem; 1999 Dec; 45(12):2150-7. PubMed ID: 10585347
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma.
Jung K; Lein M; Ringsdorf M; Roigas J; Schnorr D; Loening SA; Staack A
J Urol; 2006 Oct; 176(4 Pt 1):1326-31. PubMed ID: 16952623
[TBL] [Abstract][Full Text] [Related]
33. Biology and clinical significance of tartrate-resistant acid phosphatases: new perspectives on an old enzyme.
Janckila AJ; Yam LT
Calcif Tissue Int; 2009 Dec; 85(6):465-83. PubMed ID: 19915788
[TBL] [Abstract][Full Text] [Related]
34. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model.
Rissanen JP; Suominen MI; Peng Z; Halleen JM
Calcif Tissue Int; 2008 Feb; 82(2):108-15. PubMed ID: 18084692
[TBL] [Abstract][Full Text] [Related]
35. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
[TBL] [Abstract][Full Text] [Related]
36. Usefulness of biochemical markers of bone turnover in rats after clodronate administration.
Díaz Diego EM; de la Piedra C
Miner Electrolyte Metab; 1993; 19(6):368-72. PubMed ID: 8164618
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of tartrate-resistant acid phosphatase (TRACP) 5b as bone resorption marker in irradiated bone metastases.
Mose S; Menzel C; Kurth AA; Obert K; Ramm U; Eberlein K; Boettcher HD; Pichlmeier U
Anticancer Res; 2005; 25(6C):4639-45. PubMed ID: 16334155
[TBL] [Abstract][Full Text] [Related]
38. Tartrate-resistant acid phosphatase as a serum marker of bone resorption.
Halleen JM; Ranta R
Am Clin Lab; 2001 Jul; 20(6):29-30. PubMed ID: 11480390
[No Abstract] [Full Text] [Related]
39. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
[TBL] [Abstract][Full Text] [Related]
40. Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients.
Yao NS; Wu YY; Janckila AJ; Ku CH; Hsieh AT; Ho CL; Lee SH; Chao TY
Clin Chim Acta; 2011 Jan; 412(1-2):181-5. PubMed ID: 20932965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
